Substituted Indole CFB Inhibitors for Sustained Complement Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents targeting the complement system, such as C5 monoclonal antibodies, show variability in efficacy and do not effectively inhibit both C3 and C5 levels, leaving a need for potent compounds that can sustainably block the complement alternative pathway to treat chronic kidney diseases and other complement-mediated disorders.
Innovation Solution
Development of substituted indole compounds that act as inhibitors of complement factor B (CFB), a key enzyme in the alternative pathway, to provide therapeutic benefits in treating or preventing autoimmune, inflammatory, neurological, pulmonary, cardiovascular, and kidney diseases by blocking the central amplification loop and terminal complement pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents targeting the complement system are used, then some complement activity is inhibited, but effective inhibition of both C3 and C5 levels is not achieved, leading to variability in patient response
Solution Approach 1:
The indole compound is designed to simultaneously inhibit multiple complement components (CFB, C3, and C5) through a single agent, achieving broad-spectrum complement pathway blockade. This multi-functional inhibition addresses the limitation of current agents that only target specific complement levels, thereby improving therapeutic reliability across diverse complement-mediated diseases.
Solution Approach 2:
The patent combines multiple complement-inhibiting activities into a single molecular entity (the indole compound). By merging CFB inhibition, C3 conversion inhibition, and C5 activation inhibition into one compound, the therapy achieves comprehensive complement pathway suppression that current separate agents cannot accomplish, reducing variability in patient response.
2Duration of action of stationary object
If current complement-targeted therapies are administered, then some disease progression is slowed, but sustained complement inhibition is not achieved, resulting in limited therapeutic benefit
Solution Approach 1:
The indole compound establishes continuous complement pathway inhibition by simultaneously blocking multiple sequential steps (CFB activation, C3 conversion, and C5 activation). This multi-point blockade ensures sustained suppression of complement activity over time, preventing the rebound effects seen with single-point inhibition and delivering consistent therapeutic benefit.
3Reliability
If broader complement pathway inhibition is implemented, then therapeutic benefit is improved, but the complexity of the inhibition mechanism increases
Solution Approach 1:
The indole compound alters the biochemical parameters of complement component interactions by binding to and inhibiting FCB, C3, and C5 at their activation interfaces. This parameter change (inhibition constant, binding affinity) across multiple targets achieves broad pathway suppression while the compound's molecular structure remains a single defined entity, managing complexity through standardized interaction mechanisms.
Data Source
AI summary
Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are compositions comprising the compounds and methods of use thereof. The compounds provided are useful in the treatment, prevention or amelioration of a disease, condition or disorder through inhibition of the complement alternative pathway.